Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

Revenue up 5% in the quarter to $5.7 billion.

By: Contract Pharma

Contract Pharma Staff

Lilly
3Q Revenues: $5.7 billion (+5%)
3Q Earnings: $1.2 billion (-4%)  
YTD Revenues: $17.0 billion (+6%)
YTD Earnings: $4.1 billion (+14%)
Comments: Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth and represented approximately 52% of total revenue for the quarter. Talz sales were $454.5 million, up 34%. Trulicity sales were up 9% to $1.1 billion. Verzenio sales were up 49% to $234.4 million. Jardiance sales were $310.8 million, up 29%. Olumiant sales were up 41% to $162 million. Cyramza sales were up 5% to $252.7 million. Forteo sales declined 28% to $266.9 million. Revenue in the U.S. increased 3% to $3.2 billion, driven by a 7 percent increase in volume, partially offset by a 4 percent decrease due to lower realized prices. Revenue outside the U.S. increased 7% to $2.6 billion, driven by a 12 percent increase in volume and a 1 percent increase due to the favorable impact of foreign exchange rates, partially offset by a 7 percent decrease due to lower realized prices. In the quarter, Lilly submitted an initial request to the U.S. FDA for Emergency Use Authorization for bamlanivimab (LY-CoV555) monotherapy in higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters